VOLUME 18 | NUMBER 5 | MAY 2015 nature neurOSCIenCe a r t I C l e S In sexually reproducing species, the developing brain is either masculinized or feminized in a manner that assures adult neural physi ology and reproductive behavior are consistent with the differentiated gonads. In mammals, feminization of the brain is independent of the ovary and therefore considered a default developmental pathway that does not require active secretion of ovarian steroids. Masculinization is the differentiation away from the female phenotype and is medi ated by gonadal steroids generated by the fetal testis during a perina tal sensitive period. Chromosome complement and environmental variables either magnify or diminish sex differences in the brain, but the actions of testosterone and its potent metabolite estradiol are the most robust mediators of rodent brain masculinization 1,2 . Steroids bind to nuclear receptors that are members of an extended family of transcription factors 3 , and the direct induction of gene expression via activation of estrogen receptors (ERs) and androgen receptors (ARs) has been the presumptive route for brain masculinization 4,5 , yet few gene candidates have been identified [6] [7] [8] .
a r t I C l e S
In sexually reproducing species, the developing brain is either masculinized or feminized in a manner that assures adult neural physi ology and reproductive behavior are consistent with the differentiated gonads. In mammals, feminization of the brain is independent of the ovary and therefore considered a default developmental pathway that does not require active secretion of ovarian steroids. Masculinization is the differentiation away from the female phenotype and is medi ated by gonadal steroids generated by the fetal testis during a perina tal sensitive period. Chromosome complement and environmental variables either magnify or diminish sex differences in the brain, but the actions of testosterone and its potent metabolite estradiol are the most robust mediators of rodent brain masculinization 1, 2 . Steroids bind to nuclear receptors that are members of an extended family of transcription factors 3 , and the direct induction of gene expression via activation of estrogen receptors (ERs) and androgen receptors (ARs) has been the presumptive route for brain masculinization 4, 5 , yet few gene candidates have been identified [6] [7] [8] .
The most robust and reliable brain sexual dimorphisms are found in the preoptic area (POA), consistent with its central role in male copulatory behavior and control of gonadotropin secretion from the anterior pituitary 9, 10 . In the neonatal male rodent, estradiol aroma tized in the POA from testicular androgens induces large changes in regional volume and cell number, increases astrocyte stellation and triggers a twofold increase in putative excitatory synapses, as indi cated by increased dendritic spine density on POA neurons 1 . All of these changes are established in the first few days following birth and endure until adulthood, but it has been unknown how these devel opmental, hormonally induced changes in the brain are maintained across the lifespan.
Epigenetic processes are a means by which endogenous and exoge nous cues exert longterm control over gene expression. DNA methyla tion, which occurs predominantly at the 5′ position of cytosine residues adjacent to guanines (referred to as CpG sites), is frequently associated with longterm transcriptional repression by altering proteinDNA interactions and, ultimately, chromatin conformation. The neuronal DNA methylome is highly modifiable, with rapid demethylation and de novo methylation occurring in response to changes in excitability, particularly in genes associated with neural plasticity 11 . To deter mine whether DNA methylation contributes to estradiolmediated brain masculinization, we measured the activity and expression of DNA methyltransferase (Dnmt) enzymes in the POA of male, female and estradioltreated masculinized female rat pups and disrupted Dnmt activity in the brains of both rats and mice. We also mea sured the level of DNA methylation globally and via wholegenome bisulfite sequencing. Females had higher levels of methylation, with significantly more fully methylated CpG sites than males. Our results demonstrate that hormonally mediated decreases in Dnmt activity result in masculinization of the POA and copulatory behavior, and that feminization must be actively maintained by DNA methylation.
RESULTS
Males have lower Dnmt activity in the neonatal POA than females Total Dnmt activity in POA tissue from males was lower than activ ity in females on postnatal day 0 (PN0) and PN2 and was variable at PN4 ( Fig. 1a and Supplementary Fig. 1 ). There were no sex differ ences outside of the sensitive period, on embryonic day 20 or PN14 ( Supplementary Fig. 1 ). Treatment of newborn female rats with a mas culinizing dose of estradiol decreased Dnmt activity to that of males a r t I C l e S within 6 h and the lower activity was maintained until PN2. By PN4, activity levels dropped in normal females to match those of males and masculinized females and dropped still further in all animals by PN7 (Fig. 1a) . Treatment with estradiol on PN14, following the close of the sensitive period, no longer affected Dnmt activity (Supplementary Fig. 1 ). In the POA, levels of global DNA methylation measured on PN1 paralleled levels of Dnmt activity (Fig. 1b) . Wholegenome bisulfite sequencing revealed that this sex difference was restricted to highly methylated CpG sites (>90%), which are the majority, and that females had nearly twice the level of fully (100%) methylated CpG sites as males or masculinized females ( Fig. 1c and Supplementary Fig. 2a ). Sex differences were generally dispersed across chromosomes, although methylation on chromosome 5 and 13 was biased toward females and males, respectively (Supplementary Fig. 3 ). Sites that were 80-90% methylated were more frequent in males and masculinized females, likely revealing a population shift downward from 100% methylation, consistent with reduced or inhibited Dnmt activity ( Supplementary  Fig. 2a) . The overwhelming majority of CpG sites exhibiting a sex dif ference in methylation were in intergenic regions (~84%), followed by introns (~14%), promoter regions (~2%) and exons (<1%), and were rarely present in CpG islands (Fig. 1d) . The proportion of differences in CpG methylation might reflect the distribution of CpG sites through out different genomic regions and may not necessarily indicate an enrichment of sex differences in a specific genomic compartment. High percentages of CHG methylation were substantially lower in frequency than CpG methylation, as expected. Estradiol significantly reduced the number of CHG sites with less than 10% methylation compared with males and control females (P < 0.0001), and males and masculinized females had more CHG sites with 10-20% methylation compared with control females (P < 0.0001) (Supplementary Fig. 2b ).
There were no sex differences in mRNA or protein levels of either the maintenance Dnmt1 or de novo Dnmts, Dnmt3a and Dnmt3b ( Fig. 1e and Supplementary Fig. 4 ). Based on relative units, Dnmt1 and Dnmt3b mRNA were most abundant at birth, but levels of both of these enzymes sharply decreased in 1 week, whereas Dnmt3a levels increased by PN2 and remained elevated and substantially more abun dant than the other Dnmts until at least PN7 (Fig. 1e) . There was no hormonal modulation of mRNA or protein levels of any of the Dnmts ( Fig. 1e and Supplementary Fig. 4 ), suggesting that enzyme activity is modulated indirectly via substrate availability, phosphorylation or other means unrelated to transcription.
Low levels of Dnmt activity masculinize the bipotential brain Exogenous estradiol treatment of newborn female rat pups reliably masculinizes the POA and sexual behavior 1 . The marked decrease in fully methylated CpGs following estradiol treatment of females led us Figure 1 Females have higher Dnmt activity and DNA methylation in the POA, which is reduced by estradiol treatment. (a) On PN0 and PN2, females had significantly higher levels of Dnmt activity in the POA than males and females treated with 100 µg estradiol (e) at birth and killed 6 (on PN0) or 48 h later (on PN2, two-way ANOVA, F sex (2, 64) = 10.1, P = 0.0002). Dnmt activity decreased in all groups by PN7 (F age (3, 64) = 76.85, P < 0.0001, F int (6, 64) = 3.72, P = 0.0031). (b) On PN1, females had higher percent levels of global DNA methylation in the POA than males. 24 h of estradiol treatment significantly reduced global DNA methylation in the female POA to the level of males (ANOVA, F(2,12) = 5.55, P = 0.0197). (c) Whole-genome bisulfite sequencing revealed that females had more fully methylated CpG sites across the genome than males and estradiol-treated females (ANOVA, F(2,6) = 6.594, P = 0.0306). (d) Pie charts displaying the distribution of sex differences in CpG methylation across genomic compartments and within/outside of CpG islands and shores. Sex differences in CpG methylation were most prevalent in intergenic regions, outside of CpG islands and shores (based on 1,242 sex differences in CpG methylation). (e) Two-way ANOVA on qPCR analyses of Dnmt1, Dnmt3a and Dnmt3b detected no sex differences or hormonal modulation in the amount of mRNA in the POA at any given age across groups (Dnmt1 F sex (2,54) = 0.661, P = 0.5205, Dnmt3a F sex (2,54) = 0.024, P = 0.975, Dnmt3b F sex (2,54) = 0.013, P = 0.9867), although there was a significant decline between PN0 and PN7 in Dnmt1 (F Age (3,54) = 36.19, P < 0.0001, F int (6,54) = 0.8851, P = 0.5123) and Dnmt3b expression (F Age (3,54) = 20.46, P < 0.0001, F int (6,54) = 0.555, P = 0.7634), whereas Dnmt3a expression increased between PN0 and PN2 (F Age (3,54) = 51.46, P < 0.0001, F int (6,54) = 1.323, P = 0.2629). PN0, n = 6 male, female, and female + estradiol; PN2, n = 7 male, 4 female, 5 female + estradiol; PN4, n = 6 male, female, and female + estradiol; PN7, n = 7 male, female, and female + estradiol (a), n = 5 male, female, and female + estradiol (b), n = 3 male, female, and female + estradiol (c,d), Dnmt1: PN0, n = 5 male, 6 female, 5 female + estradiol; PN2, n = 6 male, female, and female + estradiol; PN4, n = 5 male, 5 female, 6 female + estradiol; PN7, n = 6 male, 5 female, 5 female + estradiol; Dnmt3a: PN0, n = 5 male, 6 female, 5 female + estradiol; PN2, n = 6 male, female, female + estradiol; PN4, n = 5 male, 5 female, 6 female + estradiol; PN7, n = 6 male, 5 female, 5 female + estradiol. Dnmt3b: PN0, n = 5 male, 6 female, 5 female + estradiol; PN2, n = 6 male, female, female + estradiol; PN4, n = 5 male, 5 female, 6 female + estradiol; PN7, n = 6 male, 5 female, 5 female + estradiol (e). *P < 0.05 in control females versus other groups, **P < 0.01 in control females versus other groups. Data are presented as mean ± s.e.m. to hypothesize that high levels of fully methylated CpGs in the female POA serve to repress gene expression to prevent neural and behavioral masculinization and promote feminization. We predicted that phar macological inhibition of Dnmt activity in the neonatal female brain would mimic the effects of estradiol, producing masculinized adult neuronal markers and behavior in adulthood (Fig. 2a) . We used two different Dnmt inhibitors: the lowtoxicity cytidine analog zebular ine (Zeb), which traps the enzyme in a DNA adduct 12 , but may also stimulate baseexcision repair 13 , and the smallmolecule direct inhibi tor RG108, which is targeted to Dnmt1, but considered to have broad applicability as a result of high conservation of the catalytic binding site across the Dnmts 14 . In males, endogenous estradiol induces the formation of dendritic spines on POA neurons, and these putative excitatory synapses are then maintained at twice the density of females into adulthood 6 . Neurabin II is an Factin-binding protein that is also known as spinophilin because of its enhanced localization to the postsynaptic density of dendritic spines 15 . We have found both western blot and immunohistochemical quantification of Neurabin II to be an accurate and reliable proxy marker for dendritic spines in the POA, correlating precisely with the relative spine density detected by neuroanatomical measures 6 . Moreover, Neurabin II levels in the POA of individual adult animals positively correlate with the robustness of male sexual behavior 16 , which is quantified as the number of times the masculinized animal mounts or attempts to intromit a receptive female and the latency with which these behaviors are initiated fol lowing introduction of a sexually receptive female. Intracerebroventricular (ICV) administration of Zeb or RG108 on PN0 and PN1 resulted in increased POA dendritic spine density (Fig. 2b ) and higher levels of Neurabin II in the adult female POA ( Fig. 2c and Supplementary Fig. 5b) . Notably, treatment of females with either Dnmt inhibitor masculinized adult sexual behavior. Females who received neonatal Dnmt inhibition engaged in more mounts and thrusts (intromissionlike behaviors) toward a sexually receptive female, whereas control females treated with vehicle as neonates displayed very few malelike behaviors, as expected of normally feminized animals ( Fig. 2d and Supplementary Fig. 5a ). Dnmt inhibitortreated females also had significantly shorter laten cies to mount, a measure of male sexual motivation 17 , and Zeb treat ment decreased the latency to display thrust behaviors (Fig. 2d) , n = 9 female, 9 male, 9 female + zeb, 9 male + zeb (c), Mounts: n = 8 female, 6 male, 7 female + zeb, 8 male + zeb. Thrusts: n = 8 female, 6 male, 7 female + zeb, 8 male + zeb. Mount latency: n = 8 female, 6 male, 7 female + zeb, 7 male + zeb. Thrust latency: n = 6 female, 6 male, 6 female + zeb, 7 male + zeb (d), Grid crosses: n = 8 female, 8 male, 7 female + zeb, 8 male + zeb. Rears: n = 8 female, 8 male, 7 female + zeb, 8 male + zeb. Time in center of arena: n = 8 female, 8 male, 7 female + zeb, 8 male + zeb (e). *P < 0.05, **P < 0.01, ***P < 0.001 compared with control female. # P < 0.05 compared with control male. Data are presented as mean ± s.e.m. npg a r t I C l e S activity was not impaired, but anxietyrelated behaviors were mas culinized in females following neonatal Dnmt inhibition ( Fig. 2e and Supplementary Fig. 5c ). There was no effect of Zeb treatment on estrous cyclicity (Supplementary Fig. 6 ), suggesting that the role of DNA methylation in sexual differentiation is not generalizable to other dimorphic endpoints. The efficacy of Zeb treatment at reducing CpG methylation was confirmed using the global methylation assay. Methylation was significantly reduced compared with control 24 h after ICV Zeb injection (t test, t(6) = 2.32, P = 0.0417).
Dnmt1 largely maintains DNA methylation patterns following DNA replication 18 , whereas Dnmt3a induces de novo DNA methylation in response to internal and external stimuli and is implicated in neuronal plasticity 19 , although a strong interdependence between the mainte nance and de novo Dnmts is now emerging 20 . Current pharmacological tools do not distinguish between Dnmts; thus, to gain some insight into the relative role of a specific Dnmt, we used AAV2driven conditional knockout of Dnmt3a in the neonatal mouse POA. Newborn male and female mice homozygous for a loxPflanked Dnmt3a exon (Dnmt3a loxP/loxP mice; Fig. 3a) were injected with either AAV2Cre or AAV2GFP into the POA on PN0. GFP visualization in a subset of animals confirmed viral transfection was localized to the POA (Fig. 3b) . In adulthood, 100% of AAV2Cre Dnmt3a loxP/loxP females displayed male sexual behavior, compared with 20% of control AAV2GFP Dnmt3a loxP/loxP females (Fig. 3c) . AAV2Cre Dnmt3a loxP/loxP female mice exhibited extremely fast mount latencies, long mount times and an increased number of thrusts compared with control AAV2GFP Dnmt3a loxP/loxP females. Dnmt3a knockout in the POA had no effect on activity in an open field, nor was there a sex difference in this behavior in the mice (Fig. 3d) . Significant depletion of Dnmt3a mRNA by AAV2Cre was confirmed by quantitative realtime PCR (qPCR) in adult POA from animals treated as neonates (sexes mixed, t test, t(9) = 4.691, P = 0.0011).
DNA methylation maintains the female brain phenotype AAV2mediated knockout takes days to weeks to become effective. We injected virus into the POA of mice on the day of birth, and knockout of Dnmt3a therefore may not have been fully implemented by the close of the sensitive period for sexual differentiation, suggesting that DNA methylation maintains the female brain phenotype and that mascu linization can occur if critical genes are derepressed outside of the critical period. To directly test this hypothesis, we administered Zeb to female rats outside of the sensitive period (PN10 and PN11; Fig. 4a) , and once again observed increases in Neurabin II protein levels, as well as mounting behavior in adult female rats (Fig. 4b,c) . The same treatment also reduced mount and thrust latencies. Notably, estradiol treatment of females at the same developmental time point did not mas culinize Neurabin II levels or sexual behavior, confirming the previously Immunohistochemistry was performed in a subset of animals from each experimental group to verify that the POA was targeted by AAV injection. There were no observable differences in staining intensity or cell number between groups. (c) Quantification of male sexual behavior in adult animals treated neonatally with either AAV2-Cre or AAV2-GFP revealed that 100% of the AAV2-Cre Dnmt3a loxP/loxP females displayed male sexual behavior. Appetitive components of male sexual behavior were unaffected by Dnmt3a knockout (ANOVA; solicitations, F(3,10) = 11.17, P = 0.0016; anogenital investigation, F(3,9) = 6.372, P = 0.0132), whereas AAV2-Cre females showed a significantly decreased mount latency (F(3,18) = 3.505, P = 0.036), increased mount time (F(3,16) = 7.17, P = 0.0029), and a greater number of thrusts (F(3,13) = 3.385, P = 0.051) compared to AAV2-GFP females in a 30-min trial across 3 consecutive weeks. Fig. 1 ), suggesting that at least one factor leading to the close of the sensitive period is a loss of hormonally mediated inhibition of Dnmt activity.
Methylation-dependent and -independent sex differences in gene expression If sex differences in Dnmt activity mediate differential expression of genes necessary for masculinization, then inhibiting Dnmt activity should result in masculinized patterns of gene expression. We used RNASeq to compare total gene and genetic isoform expression in the PN2 POA of males and females treated with either vehicle or Zeb on PN0 and PN1. Sex differences were observed in the expression of 70 genes with approximately half higher in males than females and vice versa (Fig. 5a and Supplementary Table 1) . Two genes, Mcpt2 and D4AD88, which code for mast cell protease 2 and an uncharacter ized protein, respectively, were exclusively expressed in the male POA. Mast cells mediate acquired immunity and have been associated with reproductive functions controlled by the brain, including the release of gonadotropin releasing hormone (GnRH) and prostaglandins 21, 22 .
Prostaglandins are critical mediators of masculinization of the POA 23 and mast cells both respond to and produce prostaglandins, thus this malespecific expression of Mcpt2 may be a critical node initiating the signal transduction cascade leading to masculinization. Only a subset of genes derepressed by Dnmt inhibition are rel evant to sexual differentiation (Fig. 5) . To identify genes involved in masculinization, we focused on those that were upregulated by Zeb in females and higher in males than in control females. We found that 24 of the 34 genes with higher expression in the male POA were signifi cantly increased by Dnmt inhibition in the female (P < 0.05; Fig. 5a ,b and Supplementary Table 2) . We considered this subset of genes to be methylationdependent gene candidates for masculinization of the brain, and regarded the ten genes that were highly expressed in males, but not Zebtreated or control females, as methylation independent candidate genes. Among the methylationdependent set was the gene cytochrome P450 19A1 (Cyp19a1; LOC100359906), which is the estradiolsynthesizing enzyme aromatase and one of the few genes previously shown to be expressed at a higher level in the male POA during the first few days after birth 24 . We confirmed the sex difference and estradiolinduced increase in Cyp19a1 mRNA with qPCR ( Supplementary Fig. 7 ), but we found that, contrary to prior assumptions, the estradiolmediated increase in Cyp19a1 was not a result of induction of transcription by ERs, but instead secondary to a loss of DNA methylation. Moreover, Cyp19a1 mRNA expression was elevated following estradiol treatment for at least another 5 d. Analysis of a large CpG island in the Cyp19a1 promoter revealed unusually high levels of CpG methylation (~50%) compared with most other candidate masculinization genes (5-8%; Supplementary  Fig. 8 ). Expression patterns of additional candidate masculinization genes (Ebf2, Efb3 and Nr2f2) were marginally higher in males, con firming our RNASeq results (Supplementary Fig. 9) .
mRNA levels of a relatively small number of genes decreased after Zeb treatment, as would be expected following demethylation, but a large percentage (22%) of them were candidate feminization genes, defined as those with higher expression in control females than in males and Zebtreated females (Fig. 5a,d ). This suggests that femini zation genes are maintained at higher levels in females versus males in a manner that involves methylation, but is opposite to that of masculinization genes, which are repressed by methylation.
Also unexpected was that 381 genes became differentially expressed when both sexes were subject to Dnmt inhibition, suggesting that some underlying sex differences in gene expression are actively suppressed by DNA methylation, resulting in a convergence, as opposed to divergence, of males and females 2, 25 (Fig. 5a) . This methylationdependent convergence in gene expression may pro Supplementary  Figure 10 . (c) Number of mounts (F (4,27) = 5.23, P = 0.003), the latency to mount (F(4,26) = 2.44, P = 0.0718, a priori t test between females and females + zeb: t(10) = 2.862, P = 0.0169), and thrust latency (F(4,21) = 6.67, P = 0.0013) were also masculinized by Dnmt inhibition whereas estradiol treatment administered at this same time point did not induce masculinization of brain or behavior. Although there were large differences in the number of thrusts between males and females (F(4,27) = 14.861, P < 0.0001), Zeb did not masculinize number of thrusts in females. n = 7 male, 7 male zeb, 6 female, 4 female + estradiol, 4 female + zeb (b). Mounts: n = 7 male, 8 male zeb, 7 female, 4 female + estradiol, 6 female + zeb. Mount latency: n = 7 male, 8 male zeb, 6 female, 4 female + estradiol, 6 female + zeb. Thrusts: n = 7 male, 8 male zeb, 6 female, 4 female + estradiol, 7 female + zeb. Thrust latency: n = 7 male, 8 male zeb, 4 female, 4 female + estradiol, 3 female + zeb (c). *P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA main effect compared with vehicle-treated female. # P < 0.05 t test compared to vehicle-treated female. Data are presented as mean ± s.e.m. 
r t I C l e S
vide an undifferentiated backdrop against which divergence in gene expression is more greatly amplified. One notable example was Foxp2: males showed increased expression after Dnmt inhibition, thereby making them different from Dnmt inhibitor-treated females.
We recently observed a sex difference in Foxp2 mRNA and protein in multiple brain regions, but the POA and hypothalamus were notable for the absence of a sex difference 26 , suggesting that there is pres sure toward convergent expression of this gene in males and females in reproductively relevant brain regions, which is achieved via DNA methylation.
DNA methylation regulates sex-specific gene isoform expression DNA methylation has been implicated in the selective expression of specific transcript isoforms via differential methylation of alternative gene promoters 27 . We detected 187 sex differences in gene isoform expression in the developing POA, far more than observed for over all gene expression. A total of 100 gene isoforms were more highly expressed in the male POA than in control females, and 87 isoforms were higher in females versus males (Fig. 5c) . One gene isoform that was more highly expressed in males than females was Ppp1r9b, which encodes Neurabin II, suggesting that the wellestablished sex difference ENSRNOT000DDD55447  ENSRNOT000DDD68168  ENSRNOT000DDD57476  ENSRNOT000DDD36556  ENSRNOT000DDD66154  ENSRNOT000DDD67823  ENSRNOT000DDD55860  ENSRNOT000DDD28829  ENSRNOT000DDD63860  ENSRNOT000DDD65545  ENSRNOT000DDDD6117  ENSRNOT000DDDD7002  ENSRNOT000DDD25172  ENSRNOT000DDD16038  ENSRNOT000DDD35438  ENSRNOT000DDD66965  ENSRNOT000DDD16568  ENSRNOT000DDD45723  ENSRNOT000DDD31907  ENSRNOT000DDD33489  ENSRNOT000DDD36512  ENSRNOT000DDD32327  ENSRNOT000DDD35009  ENSRNOT000DDD55066  ENSRNOT000DDD61036  ENSRNOT000DDD66096  ENSRNOT000DDD12549  ENSRNOT000DDD51566  ENSRNOT000DDD68665  ENSRNOT000DDD58936  ENSRNOT000DDDD9802  ENSRNOT000DDD57013  ENSRNOT000DDD23503  ENSRNOT000DDD63892  ENSRNOT000DDD44972  ENSRNOT000DDD61027  ENSRNOT000DDD67766  ENSRNOT000DDD15991  ENSRNOT000DDD65303  ENSRNOT000DDD21702  ENSRNOT000DDD11074  ENSRNOT000DDD17887  ENSRNOT000DDD45315  ENSRNOT000DDD64208  ENSRNOT000DDD66464  ENSRNOT000DDDD5726  ENSRNOT000DDD41520  ENSRNOT000DDD41994  ENSRNOT000DDD18225  ENSRNOT000DDD27304  ENSRNOT000DDD40446  ENSRNOT000DDD43509  ENSRNOT000DDD58771  ENSRNOT000DDD66152  ENSRNOT000DDD48535  ENSRNOT000DDD24740  ENSRNOT000DDD11679  ENSRNOT000DDD38727  ENSRNOT000DDD50919  ENSRNOT000DDD66495  ENSRNOT000DDD67582  ENSRNOT000DDD56437  ENSRNOT000DDD46456  ENSRNOT000DDD58983  ENSRNOT000DDD21343  ENSRNOT000DDDD9763  ENSRNOT000DDD66321  ENSRNOT000DDD24450  ENSRNOT000DDD31925  ENSRNOT000DDD64196  ENSRNOT000DDD36987  ENSRNOT000DDD59680  ENSRNOT000DDD56257  ENSRNOT000DDD45323  ENSRNOT000DDD57522  ENSRNOT000DDDD7941  ENSRNOT000DDD52270  ENSRNOT000DDD19356  ENSRNOT000DDD10209  ENSRNOT000DDD46259  ENSRNOT000DDD67591  ENSRNOT000DDD65812  ENSRNOT000DDD65955  ENSRNOT000DDD26646  ENSRNOT000DDDDD464  ENSRNOT000DDD34329  ENSRNOT000DDD37752  ENSRNOT000DDD44046  ENSRNOT000DDDD1759  ENSRNOT000DDD67155  ENSRNOT000DDD21456  ENSRNOT000DDD41140  ENSRNOT000DDD25120  ENSRNOT000DDD37199  ENSRNOT000DDD30995  ENSRNOT000DDD21642  ENSRNOT000DDD27496  ENSRNOT000DDD41218  ENSRNOT000DDD57587  ENSRNOT000DDD49805  ENSRNOT000DDD47440  ENSRNOT000DDD60857  ENSRNOT000DDD41965  ENSRNOT000DDD26197 Figure 5 Masculinization of POA gene expression by Dnmt inhibition. Animals were treated on PN0 and PN1 with Zeb. On PN2, mRNA was extracted and subject to RNA-Seq to identify methylation-dependent changes in gene expression in the female POA. (a) Schematic representation of sex differences in methylationdependent gene expression in the neonatal POA. Only 70 genes were found to be expressed at different levels in males and females, with 34 being more highly expressed in males and 36 being more highly expressed in females. Of these, 70% of genes with higher expression in males were increased in females following Dnmt inhibition, indicating methylationdependent expression. Close to half of the genes expressed at higher levels in females were decreased to male levels following Dnmt inhibition. Overall, more genes significantly changed expression in females than in males following Zeb treatment, consistent with the higher DNA methylation observed in females. Almost 400 genes became differentially expressed in males and females following Dnmt inhibition in both sexes, and are therefore referred to as convergence genes, meaning that expression is maintained at equal levels in males and females by DNA methylation. (b) Heat map of genes with basal sex differences in the POA that were also significantly altered by Zeb treatment in females. Light blue indicates lower relative expression and red indicates higher relative expression across groups. Zeb disrupted basal sex-differences in gene expression in the female POA, creating patterns resembling male gene expression. Arrow indicates the Cyp19a1 gene, which encodes the enzyme p450 aromatase, a known contributor to POA masculinization. (c) Heat map of genetic isoforms with basal sex differences that were significantly altered by Zeb treatment in females to create a male-like pattern of isoform expression. (d) Bar plot of all changes in total gene expression induced by Zeb treatment in the neonatal female POA.
Gray lines indicate genes without sex differences in expression. Blue lines indicate genes with higher expression in the control male POA versus the control female POA (putative masculinization genes). Red lines indicate genes with higher expression in the control female POA versus the control male POA (putative feminization genes). Of the genes with basal sex differences that were altered by Zeb in females, all of the male-biased genes increased in expression in females following Zeb (blue lines), and all but one of the female-biased genes decreased in expression in response to Zeb (red lines), suggesting that Dnmt inhibition masculinizes gene expression in the female POA by both increasing the expression of male-biased genes and decreasing the expression of female-biased genes. Based on data from n = 2 female, 3 Zeb female, 3 male, 3 Zeb male (not represented in plots).
npg a r t I C l e S in this proxy dendritic spine marker may arise from differential tran script expression. Using qPCR, we again confirmed higher levels of Ppp1r9b in male POA and a significant increase in females fol lowing estradiol treatment (P = 0.047; Supplementary Fig. 7b) . Moreover, 32 gene isoforms were exclusively found in the male POA (Supplementary Table 3 ), whereas 37 isoforms were exclusive to the female POA (Supplementary Table 3) . Some of the differences in iso form expression were regulated by DNA methylation, as Dnmt inhibi tion in females significantly increased the expression level of 58 of the 100 gene isoforms that normally had higher expression in males, and induced the expression of 16 of the 32 isoforms that were exclusively detected in males, creating patterns in isoform expression similar to males in Zebtreated females (P < 0.05; Fig. 5c and Supplementary Table 4 ). One notable isoform encodes drebrin 1 (Dbn1), a synaptic protein that determines dendritic spine morphogenesis in other brain regions 28 and may therefore be important for sex differences in dendritic spine density in the POA. We found that Dnmt inhibi tion in females significantly reduced the expression of 40 of the 87 isoforms that were more highly expressed in females than males, and was able to prevent the expression of 16 of the 37 isoforms exclusive to females, which are likely important for feminization of the POA (P < 0.05; Fig. 5c and Supplementary Table 4 ). Many of these gene isoforms encode proteins that are involved in basic cellular structure and physiology, such as Ank1 (Ankyrin 1) and Cacna1a, the voltage gated Ca 2+ channel Cav2.1. The potential sources of sex differences in isoform expression include differential promoter usage, splicing vari ants and parental imprinting 29 . Analysis of promoter usage revealed only 25% and 29% of male and femalebiased isoforms, respectively, resulted from alternative promoter use, suggesting that a mix of vari ables regulates sexspecific isoform expression. Many genes observed to have sexspecific isoform expression were not found to have overall differential expression, greatly amplifying both the amount and nature of sex differences in the transcriptome.
DISCUSSION
The traditional view of hormonally mediated sexual differentiation of the brain holds that steroids induce a male phenotype from the default female phenotype by binding to cognate nuclear transcription factor receptors and directly inducing expression of genes critical to brain development. This occurs during a restricted sensitive period and, once complete, the process cannot be undone. Our data chal lenge both of these views. First, we found that, in the developing POA, a principle action of the masculinizing steroid estradiol was suppression of Dnmt activity and either prevention or reversal of DNA methylation, particularly at fully methylated CpG sites. This was evident in the ability of estradiol treatment of newborn female pups to both decrease the activity of Dnmts and decrease the number of fully methylated CpGs. The high degree of consistency between measures of global methylation using an antibodybased assay and wholegenome sequencing detection of fully methylated CpGs sug gests that the antibodybased assay was biased toward fully methyl ated sites. Pharmacological inhibition of Dnmt activity mimicked the actions of estradiol and masculinized brain and behavior to the same degree as estradiol treatment during the sensitive period. Second, pharmacological inhibition of total Dnmt activity or genetic dele tion of the de novo methyltransferase Dnmt3a outside of the sensitive period was effective at masculinizing brain and behavior, confirming that feminization is an active and ongoing repression of masculiniza tion and thus reversible. NonCpG methylation is emerging as an important regulator of gene expression in the nervous system, acting as a transcriptional repressor similar to CpG methylation, and has been shown to increase in frequency during periods of synaptogenesis 30 . The majority of CHG sites had very low levels of methylation, yet there were significant sex differences; in particular, females had fewer sites with 10-20% methylation than both males and masculinized females. The number of sites that were 90-100% CHG methylated was highly variable in females compared with males and masculinized females and may be reflective of dynamic synaptogenesis at this time. A limitation of our study is the heterogeneity of cell types in our POA tissue samples, given that patterns of both CpG and CHG methylation are markedly different in neurons and glia 31 .
Inhibition of Dnmt activity resulted in decreased DNA methyla tion in a global methylation assay, an effect previously observed by others 32 . Zeb is a wellestablished demethylating agent in cancer therapy and is used to reawaken hypermethylated tumor suppres sor genes 33 . Originally thought to be a cell suicide inhibitor that irreversibly binds the Dnmts and requires cell division to be active, Zeb is now known to reversibly bind Dnmts and enhance their bind ing to unmethylated DNA. This, combined with a longhalf life, acts to sequester the Dnmts and broadly prevent their action, thereby leading to demethylation 34 . This last step is likely achieved by concomitant activity of additional enzymes such as the TET family of proteins, which convert 5methylcytosines into 5hydroxymethylcytosines. This substrate is then vulnerable to oxidation into a variety of inter mediates that are subject to base excision repair and return of the cytosine to an unmethylated state 35 . TET proteins are highly localized to gene promoters and are speculated to maintain CpG islands in a relatively demethylated state and therefore free of epigenetic repres sion 36 . Also involved are the Gadd45 enzymes, which are integral to base excision repair. Both the TET enzymes and Gadd45 are regulated by environmental factors, such as stress, and are recruiters of tran scriptional regulatory proteins including ERα 37 . We did not explore the role of TET or Gadd45, but they are established regulators of DNA demethylation in the brain 38, 39 . Thus, regardless of the final source of demethylation, our data indicate that feminization is the active process of suppressing masculinization via DNA methylation, which regulates both overall gene and specific gene isoform expression.
The concept of permanent perinatal organizational effects of steroids on the developing brain is long standing, but not without challenges. There are examples of female rodents that exhibit malelike mounting behavior either in response to adult hormone treatment 40 or conse quent to genetic manipulation 41 . These examples are used as evidence for the duality of the brain, with some arguing for the simultaneous presence of both male and female circuits or phenotypes. Our data are wholly consistent with this view and shed new light by revealing that, rather than the male genetic program simply not being induced, it is instead actively suppressed in the female by a femalespecific pattern of gene methylation. It is possible that adult hormones of appropri ate duration and dose unmask the male genetic profile by removing epigenetic marks. Moreover, changes in gene expression profile are relatively modest in the brains of adult females following gonadectomy, but are robust in males 8 , consistent with the view that females maintain tight control of sexually relevant gene expression. A similar principle appears to apply to the ovary, where the deletion of a single gene, Foxl2, results in emergence of testicular tissue in the adult 42 .
Using RNASeq, we identified differences in gene expression in the highly sexually dimorphic POA. We identified relatively few sex differences in overall gene expression and, contrary to the expecta tion that the majority of genes would be expressed at higher levels in males (as a result of predicted direct genomic transcription by ERs or ARs), we found an almost equal distribution of genes expressed at npg a r t I C l e S higher levels in males or females. Identifying genes regulating femi nization of the brain has been difficult given that it is the default developmental pathway that occurs in the absence of steroid hor mone stimulation. Our observation that Dnmt inhibition reduced a substantial number of genes in females reveals an additional layer of complexity for which there is no current explanation. There were also few sex differences in Xlinked genes. Only 1 of the 34 genes that were more highly expressed in males, and 3 of the 36 genes more highly expressed in females were X linked, suggesting that autosomal genes are important in sexual differentiation of the POA. In summary, the proximate mechanism by which females maintain control over neural gene expression clearly involves differential DNA methylation, both for preventing masculinization and allowing feminization, ultimately enabling the development of sex differences in the brain.
METhODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METhODS
Rat treatment and behavioral testing. All experiments were conducted with approval from the University of Maryland School of Medicine Institutional Care and Use Committee. Rat pups used in the following experiments were birthed by timedpregnant Sprague Dawley rats ordered from Harlan Laboratories. In all experiments, pups from multiple litters were randomly assigned to experimental treatment and then randomly distributed back to dams to control for differences in maternal care. Pregnant females were isolated and allowed to deliver normally. Cages were checked daily for the presence of pups to determine the timing of birth. All animals were allowed food and water ad libitum and were maintained on a reverse 12 h light/dark cycle. After weaning, same sex animals were caged in groups of three. 100 µg of estradiol benzoate (Sigma) was delivered subcutane ously and dissolved in sesame oil. The benzoate moiety increases solubility of the steroid and enhances deposition into muscle for slow release; it does not alter the actions of the steroid. The Dnmt inhibitors zebularine (Zeb, 300 ng in 1% DMSO, vol/vol; Calbiochem) or RG108 (300 ng in 10% DMSO; Tocris) were admin istered intracerebroventricularly (ICV) to cryoanesthetized pups under bright light illumination, allowing for visualization of the cranial landmark bregma to approximate the location of the lateral ventricle. A 23gauge, 1µl Hamilton syringe was lowered 2 mm below the surface of the skull to reach the ventricle. ICV injections were delivered bilaterally. Each hemisphere was infused with a 1µl volume of drug delivered over 60 s. Following subcutaneous and ICV hormone/drug treatments, animals received small subcutaneous injections of ink on the paw for treatment group identification. Tissue used in each experiment was collected at specified time points.
At PN40 male and female rats were gonadectomized and implanted with a 30mm silastic capsule (1.57mm inner diameter, 3.18mm outer diameter) filled with crystalline testosterone (Sigma) at the nape of the neck. Implantation of these capsules mimics the circulating hormone levels typical of an adult male and allows for performance of male sexual behavior in developmentally mascu linized females 6 . 3 weeks following surgery and testosterone replacement, male sexual behavior was assessed. Animals were video recorded for 30 min between the hours of 12 p.m. and 4 p.m., in a Plexiglas behavioral arena in the presence of a hormonally primed, sexually receptive stimulus female. Parameters of male sexual behavior quantified were the number of mounts, latency to first mount, number of intromissionlike behaviors (thrusts) and latency to first intromission like behavior, previously described 44 . Behavior in an open field was used to assess anxietyrelated behavior (time spent in center of the arena) and locomotor activity (grid crosses and rears). Rats were placed in the arena for 5 min each. Assessment of locomotor activity and male sexual behavior was conducted under dim red light during the dark phase of the animal's light cycle. The observer was blind to the experimental treatment of each animal. Data generated during behavioral testing were analyzed by oneway analysis of variance (ANOVA). All ANOVAs were followed by Tukey's post-hoc comparisons to determine group differences. D' Agostino and Pearson omnibus normality tests indicated that these and all other parametric data were normally distributed. Statistical significance was set at α = 0.05. Statistical analyses for all behavioral tests were performed in GraphPad Prism for Mac OS X (version 6.00, GraphPad Software).
Estrous cyclicity was assessed in a separate group of female rats, injected with Zeb or vehicle on PN0 and PN1 as described above, and raised to adulthood. Around PN40 vaginal smears were performed between 10 and 11 a.m. daily for 15 consecutive days. Cells were viewed at 10× magnification and each animal was described as in diestrus, proestrus or estrus each day, based on the shape and density of cells as previously described 45 . t tests were used to assess differences in the number of days spent in each stage of estrus between groups. Statistical significance was set at α = 0.05. Data were graphed in R 46 .
golgi-cox labeling and quantification. Labeling was based on Glaser and Van der Loos 47 . Briefly, deeply anesthetized rats were transcardially perfused with ice cold saline for approximately 5 min. Brains were removed and placed in COX solu tion (K 2 Cr 2 O 7 , HgCl 2 , K 2 CrO 4 ) for 3 weeks. COX solution was replaced every 3 d. Brains were transferred to Solution C (RapidGolgi Kit, FD) for 3 d at 4 °C. Brains were sectioned on a cryostat at 100 µm and mounted onto slides. Slides were placed in the dark to dry for 1 week. Slides were rinsed in dH 2 O, incubated in NH 4 OH, rinsed again in dH 2 O, incubated in 1% Kodak Dektol (wt/vol), rinsed again, then fixed in 18% Kodak Fix. Neurons were traced using Neurolucida (MBF Biosciences) interfaced with a Nikon Eclipse E600 microscope at 40× magnification.
conditional deletion of dnmt3a and behavioral testing in mice. All experi ments were conducted with approval from the Mt. Sinai School of Medicine Institutional Care and Use Committee. Dnmt3a loxP/loxP mice were originally gen erated in the laboratory of En Li at Novartis Institutes of Biomedical Research 43 . They were backcrossed with 129Jae mice for several generations to generate a common genetic background. At the Ichan School of Medicine at Mt. Sinai, male and female pups from 6 litters were bilaterally infused into the POA with 0.23 µl of AAV (1.5 × 10 8 infectious units per ml) expressing control GFP or Cre/GFP on the day of birth or PN1. Injections were performed with a fixed needle 1µl Hamilton syringe on cryoanesthetized pups. Bilateral injections were made 0.5 mm lateral to bregma to a depth of 2.5 mm and infused over a 60s period. Group identification was achieved by injection of India ink into the paws. Animals were warmed by a heating pad and returned to the dam when fully active. At ~70 d of age all animals were gonadectomized under anesthesia (ketamine/acepromazine, 0.25 ml) and implanted with a testosterone releasing silastic capsule that produces adult male circulating levels within 2-3 weeks. Animals were group housed, five per cage, by sex until behavioral testing.
Stimulus females were gonadectomized as above and implanted with estradiol releasing silastic implants to induce sexual receptivity. On the day of testing subject animals were placed in test cages for 30 min before the introduction of a sexual receptive stimulus female and behavioral interactions videotaped for 30 min. Testing was conducted at 3-5d intervals for a total of three tests. All test ing started at 6 p.m. and was performed under red light conditions. Behavioral scoring was done by an investigator blind to experiment group and followed previously established protocols for mice 48, 49 . Briefly, animals were assessed for duration of anogenital investigation, number of solicitations, mounts and thrusts, mount time and latency, thrust rate and percentage of animals performing male sex behavior. At the completion of behavioral testing a subset of animals was killed and perfused for detection of GFP in the POA.
Immunohistochemistry. Mouse brain sections were frozen sectioned at 45 µm, blocked with 10% normal goat serum (NGS, vol/vol) in PBS + 0.4% Triton X100 (vol/vol, PBST), incubated overnight at 4 °C in antiserum to GFP (Aves #1020, 1:3,000; 1DegreeBio ID: 1DB0010000745552) in PBST + 5% NGS, subsequently rinsed and incubated for 2 h in goat antichicken IgG conjugated to Alexa Fluor 488 (Invitrogen, 1:333) in PBST + 5% NGS, mounted, and cover slipped with VectaShield Hard Set (Vector Laboratories). Sections were imaged with an Olympus BX51 microscope coupled to a cooled CCD camera. Injection site accuracy into the POA was confirmed via GFP staining in all mice used for behavioral experiments. nuclear extraction and western blot. Nuclear extracts were generated from POA dissections using the EpiQuik Nuclear Extraction Kit (Epigentek) using the manufacturer's protocol. Protein concentrations were determined by Bradford assay. Nuclear extracts were used immediately or frozen at −80 °C until use in the Dnmt activity assay or for quantification of Dnmt protein levels by western blot.
Protein concentrations of 10 µg per 20µl were electrophoresed in separate lanes on an 8-16% SDSpolyacrylamide gel (Invitrogen) and transferred to a polyvinyl diflouride membrane (BioRad). Membranes were blocked in 5% nonfat milk (wt/vol) in 0.1% Tween TBS (vol/vol, TTTBS) for 1 h at 23-24 °C and then incubated overnight at 4 °C in either antiDnmt1 (Santa Cruz, cat. no. SC-20701; 1:2,000; 1DegreeBio ID: 1DB0010001405395), antiDnmt3a (Cell Signaling, cat. no. 2160; 1:1,000; 1DegreeBio ID: 1DB0010000807788), antiDnmt3b (Cell Signaling, cat. no. 2161; 1:1,500; 1DegreeBio ID: 1DB001 0000807789) or antiNeurabin (Millipore, cat. no. 06-852; 1:1,000; 1DegreeBio ID: 1DB0010000850617) in 2.5% milk in TTBS, followed by a 30min incuba tion in goat antirabbit HRP conjugated IgG (Cell Signaling; 1:3,000) in TTBS. The Phototope chemiluminescence system (New England BioLabs) was used for detection of proteins recognized by the antisera. The blots were exposed to HyperfilmECL (Amersham) for varying amounts of time (1-10 min). After visualization, membranes were washed briefly with distilled water and stained with Ponceau S solution. The dense protein band stained by Ponceau S appearing at approximately 45 kDa was used for standardization to correct errors in sample loading. The band appearing at approximately 45 kDa contains a large number of proteins ranging in size from 43-47 kDa, which reduces the possibility of a treatment effect on any one control protein. 
